Clinical Trial: Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07537088) titled 'Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease' on April 12.

Brief Summary: The purpose of this study is to evaluate whether adding dulaglutide to the combination therapy of SGLT2i and finerenone can provide additional kidney protection and safety for Chinese adults with T2DM and CKD. Eligible participants will be adults with T2DM and mild-to-moderate CKD who have been receiving SGLT2 inhibitor plus finerenone for at least 3 months on the basis of maximum tolerated dose of renin-angiotensin system inhibitor (RASi). Participan...